Lithium Americas Corp vs Zoetis Inc — how do they compare? Lithium Americas Corp trades at $3.3 (market cap $1.18B), while Zoetis Inc trades at $73.68 (market cap $31.14B). The key difference: Zoetis Inc is far larger — about 26.4× Lithium Americas Corp's market cap, and Zoetis Inc pays a 2.81% dividend while Lithium Americas Corp pays none. Which is the better fit depends on your goals.
| LAC | ZTS | |
|---|---|---|
Market Cap | $1.18B | $31.14B |
Sector | Basic Materials | Health |
52-Week High | $10.05 | $156.76 |
52-Week Low | $2.71 | $71.91 |
Enterprise Value | $1.29B | $38.70B |
Dividend Yield | — | 2.81% |
Signals from Pluang's Aura AI — not financial advice
Lithium Americas (LAC) trades at $3.26, showing modest daily gains of 0.31%. The stock exhibits a bullish technical signal with mixed quarterly earnings performance, beating estimates twice but missing significantly in Q4 2025. Recent $175 million financing strengthens the balance sheet as Thacker Pass approaches peak construction. The company maintains negative profitability metrics with ROE at -11.35% but trades below book value at P/B of 0.88.
Investment outlook remains speculative with significant execution risk at Thacker Pass requiring substantial capital expenditures. Analyst consensus leans cautious with 47% buy ratings versus 53% holds. Positive catalysts include lithium demand growth and government support, but cash burn and dilution risks persist for equity holders amid ongoing development phase.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Trailing returns across standard periods
Latest headlines on both assets
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →